These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 7127334)

  • 1. Six enzymes from mayapple that complete the biosynthetic pathway to the etoposide aglycone.
    Lau W; Sattely ES
    Science; 2015 Sep; 349(6253):1224-8. PubMed ID: 26359402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.
    Kok TC; Van der Gaast A; Dees J; Eykenboom WM; Van Overhagen H; Stoter G; Tilanus HW; Splinter TA
    Br J Cancer; 1996 Sep; 74(6):980-4. PubMed ID: 8826870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPIC: an effective low toxicity regimen for relapsing lymphoma.
    Hickish T; Roldan A; Cunningham D; Mansi J; Ashley S; Nicolson V; Gore ME; Catovsky D; Smith IE
    Br J Cancer; 1993 Sep; 68(3):599-604. PubMed ID: 8353050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
    Naito S; Ueda T; Kotoh S; Kumazawa J; Itoh K; Sagiyama K; Omoto T; Andoh S; Hasegawa Y; Fujisawa Y
    Cancer Chemother Pharmacol; 1995; 35(3):225-9. PubMed ID: 7805181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line.
    Hepburn PJ; Oliver RT; Riley PA; Hill BT; Masters JR
    Urol Res; 1985; 13(1):27-34. PubMed ID: 4039488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose etoposide does not cause peripheral neuropathy.
    Littlewood TJ; Bentley DP; McQueen IN
    Cancer Chemother Pharmacol; 1987; 19(2):180-1. PubMed ID: 3568278
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical pharmacology of etoposide and teniposide.
    Clark PI; Slevin ML
    Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide--chemistry, preclinical and clinical pharmacology.
    Achterrath W; Niederle N; Raettig R; Hilgard P
    Cancer Treat Rev; 1982 Jun; 9 Suppl():3-13. PubMed ID: 7127334
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 10. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
    Schmoll HJ; Niederle N; Achterrath W
    Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Sinkule JA
    Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current development of podophyllotoxins.
    Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
    Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.